DISEASES
11 px font size 12 px font size 14 px font size
APOLLO NEWSLETTER
Professor Paul
Zimmet
AO
Head of
International Diabetes Institute, Melbourne
"The data that I have seen so far makes this one of the most forward looking and best prospects of an oral insulin"
Click here to see Paul Zimmet's view on Apollo's oral insulin
Bill Moss AM
Non-Executive Director and
Investor
"Apollo has a number of opportunities to grow into the future. Opportunities perhaps that are much greater than many other companies many times their size"
Click here to hear Bill Moss's view on investing in Apollo
Diseases

Apollo’s Oral and Transdermal Delivery, combined with unique Natural Human Proteins, makes it possible to develop improved treatments for a wide range of diseases. The improvements may result from one or several of these technologies. For example, being able to deliver insulin orally will provide benefits to many people with diabetes who currently have to inject themselves several times a day. Moderate to severe psoriasis sufferers would benefit from an effective treatment that can be simply rubbed onto the skin, avoiding the need for injected treatment. And in many diseases, using human proteins with human sugar structures has the potential to provide more effective treatments with fewer side effects.

Apollo has a wide development pipeline of therapeutic candidates that offer these types of potential benefits, including: